Aprea Therapeutics’ (APRE) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Separately, Wedbush restated an outperform rating and issued a $9.00 price objective on shares of Aprea Therapeutics in a report […]
More Stories
Reed’s (NYSE: REED) Announces Completion of $10 Million Private Placement
On December 30, 2024, Reed’s Inc., a Delaware corporation, finalized a securities purchase agreement resulting in the issuance and sale...
Royal Bank of Canada Reiterates Outperform Rating for TD SYNNEX (NYSE:SNX)
TD SYNNEX (NYSE:SNX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of...
JPMorgan Chase & Co. Reaffirms Underweight Rating for Excelerate Energy (NYSE:EE)
Excelerate Energy (NYSE:EE – Get Free Report)‘s stock had its “underweight” rating reiterated by analysts at JPMorgan Chase & Co....
Wells Fargo & Company Forecasts Strong Price Appreciation for Cloudflare (NYSE:NET) Stock
Cloudflare (NYSE:NET – Get Free Report) had its price target boosted by investment analysts at Wells Fargo & Company from...
Wells Fargo & Company Lowers Parker-Hannifin (NYSE:PH) Price Target to $710.00
Parker-Hannifin (NYSE:PH – Get Free Report) had its price target cut by investment analysts at Wells Fargo & Company from...
Relx (LON:REL) Sets New 52-Week High – Here’s What Happened
Relx Plc (LON:REL – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company...